Year: 2023

Telos Corporation Announces Third Quarter Results: Exceeds Guidance on All Metrics, Significantly Expands Gross Margin, Returns to Positive Cash Flow From Operations, and Raises Full-Year Outlook

Written by Customer Service on November 9, 2023. Posted in Earnings Releases And Operating Results.

Reports Third Quarter Results Above High End of Guidance Range on All Metrics Delivered $36.2 Million of Revenue, Reflecting Outperformance by Security Solutions and Official Launch of TSA PreCheck® Program Expanded Gross Margin by 303 Basis Points Year-over-Year to 36.0%; Excluding Stock-Based Compensation and Depreciation and Amortization, Non-GAAP Gross Margin Expanded by 684 Basis Points to 41.5% Generated $0.8 Million of Cash Flow From Operations Raises Full-Year Outlook on All MetricsASHBURN, Va., Nov. 09, 2023 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, today announced financial results for the third quarter 2023. “We executed well in the third quarter, delivering results above the high end...

Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test

Written by Customer Service on November 9, 2023. Posted in Public Companies.

Collaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing BERKELEY, Calif. and MAINZ, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strategic partnership with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform (EMERGE) to serve the biopharma and diagnostics industries along with academic institutions. The collaboration builds upon Mainz Biomed’s initial utilization of EMERGE to analyze the Company’s ColoFuture study, which recently reported groundbreaking results including sensitivity for colorectal cancer of 94% with a specificity of 97% and a sensitivity...

PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2023

Written by Customer Service on November 9, 2023. Posted in Public Companies.

MINNEAPOLIS, MN, US, Nov. 09, 2023 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Tuesday, November 14, 2023 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo’s Investor Relations website at: https://audience.mysequire.com/webinar-view?webinar_id=13014345-4054-48e0-b0d9-f0b425d9e51c A replay of the webcast will be available through the same link following the conference call. Participants can also access the call using the dial-in details below. Date:...

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Written by Customer Service on November 9, 2023. Posted in Earnings Releases And Operating Results.

Phase 2b open-label extension eGFR and proteinuria data expected in the first quarter of 2024; actively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept in IgAN Announced analysis of Phase 2b ORIGIN study showing resolution of hematuria in the majority of patients, at the American Society of Nephrology Kidney Week 2023 Strong balance sheet expected to fund operations to early 2026BRISBANE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today reported its business highlights and financial results for the third quarter ended September 30, 2023. “Vera presented additional positive data from the Phase 2b ORIGIN trial...

Ackroo Releases Q3 2023 Financial Results

Written by Customer Service on November 9, 2023. Posted in Earnings Releases And Operating Results.

Ackroo delivers 8% year-to-date YoY revenue growth and 24% year-to-date YOY EBITDA growth HAMILTON, Ontario, Nov. 09, 2023 (GLOBE NEWSWIRE) — Ackroo Inc. (TSX-V: AKR; OTC: AKRFF) (the “Company”), a loyalty marketing, payments and point-of-sale technology and services provider, has filed its financial results for the period ended September 30, 2023. The results for the period ended September 30th,2023 reflect 8% year-to-date year over year revenue growth and 24% year-to-date year over year adjusted EBITDA growth. During the period the Company also achieved 24% adjusted EBITDA as a percentage of total revenue increasing the year-to-date EBITDA as a percentage of revenue to 21%. The Company used $200,000 of their earnings towards share buy-backs and used the rest of the generated cash flow to reduce debt. The Company plans to continue...

Rogers Communications Reports Third Quarter 2023 Results

Written by Customer Service on November 9, 2023. Posted in Earnings Releases And Operating Results.

Rogers delivers strong results across the board as Canadians continue to choose Rogers more than any other carrier in Canada with record wireless net loadingMobile phone and Internet net adds of 279,000, up 52,000 from Q3 last year Q3 total mobile phone net adds of 261,000, up 40,000 from last year – best quarterly result ever Q3 postpaid mobile phone net adds of 225,000 – strongest loading on record Year to date postpaid mobile phone net adds of 490,000, up 39% year over year Q3 Internet net loading of 18,000, up 12,000 year over year with growth ramping in both East and WestShaw integration and synergy targets ahead of plan driven by continued strong executionIndustry-leading Cable margins of 54.2% up 650 basis points from last year Systems, networks, Rogers branding, and overall operations continuing to be integrated...

Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Written by Customer Service on November 9, 2023. Posted in Earnings Releases And Operating Results.

Announced promising preliminary clinical data for OTX-2002 from ongoing MYCHELANGELO™ I trial; clinical proof-of-platform established with potential applicability across a broad range of diseases Advanced OMEGA platform capabilities and presented new preclinical data on multiple epigenomic controller programs at medical meetings Further strengthened Board of Directors with appointment of Chris Schade as Chairman and addition of Michelle C. WernerCAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the third quarter ended September 30, 2023, and highlighted recent Company progress. “The promising initial data from...

Applied Therapeutics Reports Third Quarter 2023 Financial Results

Written by Customer Service on November 9, 2023. Posted in Public Companies.

Regulatory submissions on track for govorestat (AT-007) for the treatment of Classic Galactosemia to US FDA and EMA in 4Q 2023 Two Upcoming Phase 3 Trial Readouts, with ARISE-HF Trial of AT-001 (caficrestat) in Diabetic Cardiomyopathy on track for data readout in 4Q 2023 and INSPIRE Trial of AT-007 trial in Sorbitol Dehydrogenase (SORD) Deficiency in 1Q 2024 NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2023. “We have continued to make progress across our late-stage pipeline and have several key regulatory and clinical inflection points expected later...

Knight Therapeutics Reports Third Quarter 2023 Results

Written by Customer Service on November 9, 2023. Posted in Public Companies.

– Achieved Record Nine-month Revenues and Adjusted EBITDA MONTREAL, Nov. 09, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q3 2023 Highlights Financial ResultsRevenues were $81,500, an increase of $9,219 or 13% over the same period in prior year. Gross margin of $40,182 or 49% compared to $30,401 or 42% in the same period in prior year. Adjusted EBITDA1 was $15,512, an increase of $6,503 or 72% over the same period in prior year. Adjusted EBITDA per share1 of $0.15, an increase of $0.07 or 87%...

Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

Written by Customer Service on November 9, 2023. Posted in Public Companies.

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that the first patient has been dosed in the Phase 1b clinical trial of PH-762, an INTASYL compound that reduces the expression of PD-1, a protein that inhibits T cells’ ability to kill cancer cells. This clinical trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. “The initiation of enrollment in this trial represents...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals